



Dr Lokesh Bagari Nagappa

Sanofi-Aventis (Malaysia) Sdn Bhd (334110-P)
Unit TB-18-1, Level 18, Tower B, Plaza 33,
1, Jalan Kemajuan, Seksyen 13,
46200 Petaling Jaya, Selangor, Malaysia



Singapore, 01 June 2022

Valproate: updates to the HCP and patient guides

Dear Healthcare Professional,

This letter is to remind you of the **important safety information** with regards to the use of Epilim (Sodium Valproate), and the corresponding Valproate HCP and Patient Guides, which is in accordance with the Epilim® prescribing information that had been approved by the Health Sciences Authority (HSA), Singapore, available on the HSA website.

Information related to the risks of abnormal pregnancy outcomes in children exposed to valproate in utero, with new information on the risk of hearing impairment or deafness, updates related to the risk of ADHD have been included in these guides.

Call for reporting

Any suspected adverse events should be reported to the Health Sciences Authority (HSA), Singapore via the online adverse event reporting form available at <https://www.hsa.gov.sg/>

Company contact point

Adverse drug reactions should also be reported to Sanofi-Aventis (Singapore) Pte Ltd, pharmacovigilance mailbox PV.SIN@sanofi.com.

For further medical information on Epilim®, please contact Sanofi-Aventis (Singapore) Pte Ltd medical enquiry mailbox Med.SAMS@sanofi.com with the subject title "EPILIM".

Yours faithfully,

Lokesh BN (Jun 15, 2022 14:10 GMT+8)

Dr Lokesh B N

TMS EP Medical Lead